Skip to main content

Jennifer Goralski, MD, has been consulted for several news articles reporting the FDA’s expansion of age limits for Trikafta to treat younger children with cystic fibrosis. Dr. Goralski was a lead principal investigator in the clinical trial on which the FDA based its decision. The articles can be found at the links below:

MedPage Today: FDA Extends Trikafta Approval to Even Younger Cystic Fibrosis Patients

Cystic Fibrosis News Today: FDA expands its approval of Trikafta to children ages 2 to 5

Pulmonary Advisor: Trikafta Approved for Children With Cystic Fibrosis as Young as 2 Years

RareDiseaseAdvisor: FDA Approves Trikafta Label Expansion for Young Children With Cystic Fibrosis